Logo image of OCUL

OCULAR THERAPEUTIX INC (OCUL) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:OCUL - US67576A1007 - Common Stock

12.56 USD
-0.42 (-3.24%)
Last: 12/19/2025, 8:07:44 PM
12.74 USD
+0.18 (+1.43%)
After Hours: 12/19/2025, 8:07:44 PM
Fundamental Rating

3

Taking everything into account, OCUL scores 3 out of 10 in our fundamental rating. OCUL was compared to 192 industry peers in the Pharmaceuticals industry. OCUL scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. While showing a medium growth rate, OCUL is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year OCUL has reported negative net income.
In the past year OCUL has reported a negative cash flow from operations.
OCUL had negative earnings in each of the past 5 years.
OCUL had a negative operating cash flow in each of the past 5 years.
OCUL Yearly Net Income VS EBIT VS OCF VS FCFOCUL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

OCUL has a worse Return On Assets (-60.77%) than 65.97% of its industry peers.
OCUL has a Return On Equity of -96.69%. This is in the lower half of the industry: OCUL underperforms 62.83% of its industry peers.
Industry RankSector Rank
ROA -60.77%
ROE -96.69%
ROIC N/A
ROA(3y)-40.62%
ROA(5y)-36.9%
ROE(3y)-116.88%
ROE(5y)-112.52%
ROIC(3y)N/A
ROIC(5y)N/A
OCUL Yearly ROA, ROE, ROICOCUL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 1K 1.5K 2K

1.3 Margins

OCUL's Gross Margin of 88.87% is amongst the best of the industry. OCUL outperforms 91.10% of its industry peers.
In the last couple of years the Gross Margin of OCUL has grown nicely.
The Profit Margin and Operating Margin are not available for OCUL so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 88.87%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.47%
GM growth 5Y15.21%
OCUL Yearly Profit, Operating, Gross MarginsOCUL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K

More info and screens

5

2. Health

2.1 Basic Checks

OCUL does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, OCUL has more shares outstanding
OCUL has more shares outstanding than it did 5 years ago.
OCUL has a better debt/assets ratio than last year.
OCUL Yearly Shares OutstandingOCUL Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
OCUL Yearly Total Debt VS Total AssetsOCUL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

OCUL has an Altman-Z score of 6.25. This indicates that OCUL is financially healthy and has little risk of bankruptcy at the moment.
With a decent Altman-Z score value of 6.25, OCUL is doing good in the industry, outperforming 77.49% of the companies in the same industry.
A Debt/Equity ratio of 0.27 indicates that OCUL is not too dependend on debt financing.
The Debt to Equity ratio of OCUL (0.27) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.27
Debt/FCF N/A
Altman-Z 6.25
ROIC/WACCN/A
WACC9.86%
OCUL Yearly LT Debt VS Equity VS FCFOCUL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M

2.3 Liquidity

A Current Ratio of 7.85 indicates that OCUL has no problem at all paying its short term obligations.
The Current ratio of OCUL (7.85) is better than 72.77% of its industry peers.
OCUL has a Quick Ratio of 7.78. This indicates that OCUL is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of OCUL (7.78) is better than 73.30% of its industry peers.
Industry RankSector Rank
Current Ratio 7.85
Quick Ratio 7.78
OCUL Yearly Current Assets VS Current LiabilitesOCUL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

5

3. Growth

3.1 Past

OCUL shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 5.88%.
The Revenue has decreased by -9.21% in the past year.
The Revenue has been growing by 72.02% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)5.88%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-72.73%
Revenue 1Y (TTM)-9.21%
Revenue growth 3Y13.55%
Revenue growth 5Y72.02%
Sales Q2Q%-5.71%

3.2 Future

Based on estimates for the next years, OCUL will show a quite strong growth in Earnings Per Share. The EPS will grow by 17.24% on average per year.
The Revenue is expected to grow by 55.40% on average over the next years. This is a very strong growth
EPS Next Y-1.41%
EPS Next 2Y2.39%
EPS Next 3Y4.64%
EPS Next 5Y17.24%
Revenue Next Year-13.93%
Revenue Next 2Y-0.56%
Revenue Next 3Y11.68%
Revenue Next 5Y55.4%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
OCUL Yearly Revenue VS EstimatesOCUL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 500M 1B 1.5B 2B
OCUL Yearly EPS VS EstimatesOCUL Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 1 -1 -2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

OCUL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for OCUL. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
OCUL Price Earnings VS Forward Price EarningsOCUL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
OCUL Per share dataOCUL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y2.39%
EPS Next 3Y4.64%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for OCUL!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

OCULAR THERAPEUTIX INC

NASDAQ:OCUL (12/19/2025, 8:07:44 PM)

After market: 12.74 +0.18 (+1.43%)

12.56

-0.42 (-3.24%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-04 2025-11-04/bmo
Earnings (Next)03-02 2026-03-02/amc
Inst Owners88.38%
Inst Owner Change19.84%
Ins Owners2.22%
Ins Owner Change-1.02%
Market Cap2.68B
Revenue(TTM)55.78M
Net Income(TTM)-249.67M
Analysts86.32
Price Target22.78 (81.37%)
Short Float %5.63%
Short Ratio3.81
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-4.72%
Min EPS beat(2)-7.83%
Max EPS beat(2)-1.62%
EPS beat(4)0
Avg EPS beat(4)-12.26%
Min EPS beat(4)-26.63%
Max EPS beat(4)-1.62%
EPS beat(8)1
Avg EPS beat(8)-40.57%
EPS beat(12)4
Avg EPS beat(12)-25.42%
EPS beat(16)6
Avg EPS beat(16)-13.78%
Revenue beat(2)0
Avg Revenue beat(2)-1.48%
Min Revenue beat(2)-2.51%
Max Revenue beat(2)-0.44%
Revenue beat(4)0
Avg Revenue beat(4)-10.82%
Min Revenue beat(4)-37.69%
Max Revenue beat(4)-0.44%
Revenue beat(8)1
Avg Revenue beat(8)-8.36%
Revenue beat(12)3
Avg Revenue beat(12)-6.11%
Revenue beat(16)3
Avg Revenue beat(16)-8.25%
PT rev (1m)6.35%
PT rev (3m)27.29%
EPS NQ rev (1m)2.35%
EPS NQ rev (3m)15.58%
EPS NY rev (1m)0.07%
EPS NY rev (3m)4.4%
Revenue NQ rev (1m)2.46%
Revenue NQ rev (3m)0.02%
Revenue NY rev (1m)-0.23%
Revenue NY rev (3m)0.14%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 47.97
P/FCF N/A
P/OCF N/A
P/B 10.36
P/tB 10.36
EV/EBITDA N/A
EPS(TTM)-1.44
EYN/A
EPS(NY)-1.4
Fwd EYN/A
FCF(TTM)-0.94
FCFYN/A
OCF(TTM)-0.89
OCFYN/A
SpS0.26
BVpS1.21
TBVpS1.21
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -60.77%
ROE -96.69%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 88.87%
FCFM N/A
ROA(3y)-40.62%
ROA(5y)-36.9%
ROE(3y)-116.88%
ROE(5y)-112.52%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.47%
GM growth 5Y15.21%
F-Score2
Asset Turnover0.14
Health
Industry RankSector Rank
Debt/Equity 0.27
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 232.75%
Cap/Sales 16.8%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.85
Quick Ratio 7.78
Altman-Z 6.25
F-Score2
WACC9.86%
ROIC/WACCN/A
Cap/Depr(3y)138.13%
Cap/Depr(5y)98.78%
Cap/Sales(3y)6.55%
Cap/Sales(5y)5.44%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)5.88%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-72.73%
EPS Next Y-1.41%
EPS Next 2Y2.39%
EPS Next 3Y4.64%
EPS Next 5Y17.24%
Revenue 1Y (TTM)-9.21%
Revenue growth 3Y13.55%
Revenue growth 5Y72.02%
Sales Q2Q%-5.71%
Revenue Next Year-13.93%
Revenue Next 2Y-0.56%
Revenue Next 3Y11.68%
Revenue Next 5Y55.4%
EBIT growth 1Y-77.57%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-59.56%
EBIT Next 3Y-22.63%
EBIT Next 5Y19.4%
FCF growth 1Y-175.05%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-193.62%
OCF growth 3YN/A
OCF growth 5YN/A

OCULAR THERAPEUTIX INC / OCUL FAQ

What is the ChartMill fundamental rating of OCULAR THERAPEUTIX INC (OCUL) stock?

ChartMill assigns a fundamental rating of 3 / 10 to OCUL.


What is the valuation status for OCUL stock?

ChartMill assigns a valuation rating of 0 / 10 to OCULAR THERAPEUTIX INC (OCUL). This can be considered as Overvalued.


How profitable is OCULAR THERAPEUTIX INC (OCUL) stock?

OCULAR THERAPEUTIX INC (OCUL) has a profitability rating of 1 / 10.


What is the expected EPS growth for OCULAR THERAPEUTIX INC (OCUL) stock?

The Earnings per Share (EPS) of OCULAR THERAPEUTIX INC (OCUL) is expected to decline by -1.41% in the next year.